precision therapies for
eye disease
Rewriting the genetic code of Inherited Retinal Diseases — for the people who live it
Born from a collaboration between Australia's foremost eye research institution CERA and MedicVision AI, an AI-driven ophthalmology innovator, Adara Bio brings together world-class science, deep clinical expertise, and a bold commercial vision.
We exist for the patients who have been told there is no cure — because we believe that is about to change.
THE OPPORTUNITY IN NUMBERS
Addressing an Unmet Need in Inherited Retinal Diseases
01
4 Million
Patients worldwide
Over 4 million individuals suffer for Inherited Retinal Diseases, representing the leading cause of blindness among working-age adults.
02
300+
Genetic targets
The vast genetic diversity of IRDs has bottlenecked traditional gene therapies. Adara’s scalable platform is built to overcome this by targeting multiple mutations with one core editor.
03
24%
Point mutation coverage
The EDITRA™ platform is capable of correcting up to 24% of the known point mutations responsible for causing Inherited Retinal Diseases worldwide.
04
Gene Size Independent
Overcoming the Cargo Limit
Large-gene indications like USH2A and EYS exceed standard viral vector capacities. Because Adara edits RNA rather than replacing whole genes, our platform is completely independent of gene size.
OUR PEOPLE
Complementary leadership.
Proven concept-to-clinic experience.
Rick Liu
Founder & CSO
Inventor of Adara Bio's core RNA platform;
Leader in Genetic engineering.
Stanley Chang
Director
Chairman of Medigen Biomedical Group, with executive experience in drug development ,vaccines, molecular diagnostics and opthalmic generics.
Jitto Arulampalam
Chair
Business executive , investor and entrepreneur,
co-founder of RedOwl Pty Ltd.
Emily Lee
Alternate Director
Melbourne-based businesswoman with a substantial track record in cross-border transactions and corporate finance across Australia and Asia.
Darren Kelly
Executive Director
Biotech CEO and founder with a proven track record of building advanced therapy companies from concept to acquisition.
Keith Martin
CMO
Managing Director- CERA, Director of Research of Australian Vision Research, former Professor and Head of Ophthalmology and Deputy Director- Centre for Brain Repair -University of Cambridge.
Shereen Tan
Director & COO
Commercial and business development leader wit expertise in early-stage biotech and commercial strategy.
OUR INVESTORS, PARTNERS & SPONSERS
OUR TECHNOLOGY
One Platform.
Many Corrections.
Adara Bio's RNA re-writing platform, EDITRA™ is designed to address the genetic diversity of Inherited Retinal Diseases (IRDs). By precisely correcting disease-causing mutations at the RNA level, EDITRA™ provides a flexible and adaptable approach that can be programmed for different genetic targets while avoiding permanent changes to DNA.
The platform is designed to enable the development of a scalable pipeline of precision therapies for retinal diseases with significant unmet medical need.
Safer by design
Targets RNA , not DNA.
No permanent changes to the genome.
EDITRA™ enables precise RNA editing to correct a wide range of disease-causing mutations.
One Scalable Platform. Many Diseases. Transformative Potential.
Clinic-ready delivery
Designed foe efficient delivery to retinal cells with AAV.
Adaptable
Programmable to address different mutations across multiple genes.
OUR PIPELINE
OUR LATEST NEWS
Latest Press Releases
& Community News
Resource Name
Resource Name
Resource Name
This is the space to provide tools, guides, and materials to help visitors learn more about your industry or services.
This is the space to provide tools, guides, and materials to help visitors learn more about your industry or services.
This is the space to provide tools, guides, and materials to help visitors learn more about your industry or services.